Uncategorized
STAT+: GSK advancing ovarian cancer drug mo-rez
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
It’s been a minute since I’ve wished you a good morning. Morning!
We’ve got some big news on Revolution Medicines’ pancreatic cancer treatment. But don’t miss GSK’s move to push an ovarian cancer ADC into five Phase 3 trials after striking early data. And Spyre Therapeutics released some competitive ulcerative colitis results.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
It’s been a minute since I’ve wished you a good morning. Morning!
We’ve got some big news on Revolution Medicines’ pancreatic cancer treatment. But don’t miss GSK’s move to push an ovarian cancer ADC into five Phase 3 trials after striking early data. And Spyre Therapeutics released some competitive ulcerative colitis results.